A 1 AR Brain (cortex, hippocampus, cerebellum), spinal cord, eye, adrenal gland, atria, liver, kidney, adipose tissue, salivary glands, esophagus, colon, atrium and ...
iTeos Therapeutics (ITOS) is gearing up to report results from several of its programs in 2024. I believe that investors can benefit here, because there is potential with multiple shots on goal.
Acquires two clinical-stage, best in class adenosine compounds, and two preclinical assets for approximately $21 million upfront consideration Rob Glassman, M.D., Ph.D., director of Tarus and former ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results